The effectiveness of ¹⁶⁶Ho-chitosan complex as a radiopharmaceutical for trans-arterial radiation therapy of liver cancer has been established in clinical trials. We have developed a simple kit-bade strategy for convenient formulation of therapeutically relevant doses of ¹⁶⁶Ho-chitosan complex in a hospital radiopharmacy in order to facilitate its widespread utilization. Quality control studies established the suitability of the radiopharmaceutical formulated using the developed strategy for in vivo administration. Biodistribution studies in normal Wistar rats showed excellent retention of the radiopharmaceutical in the liver, thus, paving the way towards utility of this approach in clinical context.

在临床试验中已经确定了¹⁶⁶ Ho-壳聚糖复合物作为肝癌经动脉放射治疗的放射性药物的有效性。我们已经开发了一种简单的试剂盒策略，可以方便地在医院的放射药房中配制治疗相关剂量的¹⁶⁶ Ho-壳聚糖复合物，以促进其广泛使用。质量控制研究确定了使用已开发的体内给药策略配制的放射性药物的适用性。在正常Wistar大鼠中进行的生物分布研究表明，放射性药物在肝脏中具有出色的滞留性，因此为在临床中应用该方法铺平了道路。